Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Open Access
- 15 July 2007
- journal article
- retracted article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (14), 4280-4290
- https://doi.org/10.1158/1078-0432.ccr-07-0835
Abstract
Purpose: Interactions between the multikinase inhibitor sorafenib (Bay 43-9006) and the histone deacetylase inhibitor vorinostat were examined in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate.Keywords
This publication has 52 references indexed in Scilit:
- Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutantBlood, 2006
- BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesionOncogene, 2006
- Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cellsMolecular Cancer Therapeutics, 2005
- Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cellsLeukemia, 2005
- Puma*Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1Oncogene, 2005
- Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotidesBlood, 2005
- Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activityCell Death & Differentiation, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21Oncogene, 1999